Novel Treatment Options in Patients with Maturity-Onset Diabetes of the Young

被引:1
|
作者
Muessig, Karsten [1 ]
机构
[1] Franziskus Hosp Harderberg, Niels Stensen Hosp, Dept Internal Med Gastroenterol & Diabetol, Alte Rothenfelder Str 23, D-49124 Georgsmarienhutte, Germany
关键词
MODY; SGLT2; inhibitor; gliflozin; DPP-4; gliptin; GLP-1 receptor agonist; GLP-1; analogue; OPTIMAL GLYCEMIC CONTROL; CLINICAL-FEATURES; PEDIATRIC-PATIENT; RECEPTOR AGONIST; HNF1-ALPHA MODY; INHIBITOR; MUTATION;
D O I
10.1055/a-2436-7723
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Maturity-onset diabetes of the young (MODY) is the most common monogenetic form of diabetes with an autosomal dominant inheritance pattern. MODY is caused by mutations in genes important for the development and function of pancreatic beta cells, resulting in impaired insulin secretion capacity. To date, 14 different types have been described. While glucokinase (GCK)-MODY (formerly MODY-2) generally requires no drug therapy, other forms of MODY, such as hepatocyte nuclear factor-1-alpha (HNF1A)-MODY (formerly MODY-3) and HNF4A (formerly MODY-1), usually respond very well to sulfonylurea therapy. However, these MODY forms are characterised by a progressive course, meaning that insulin therapy is often required as the disease progresses. Both sulfonylurea therapy and insulin therapy are associated with an increased risk of hypoglycaemia and frequent weight gain. Newer blood glucose-lowering therapies, such as SGLT2 inhibitors (SGLT2i), DPP-4 inhibitors (DPP4i) and GLP-1 receptor agonists (GLP-1RA), have a much lower risk of hypoglycaemia and usually have a favourable effect on body weight. This review aims to provide an overview of the treatment of MODY patients with SGLT2i, DPP4i and GLP-1RA on the basis of previously published clinical studies, case series and case reports.
引用
收藏
页码:51 / 58
页数:8
相关论文
共 50 条
  • [31] Genetic basis of maturity-onset diabetes of the young
    Vaxillaire, Martine
    Froguel, Philippe
    ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA, 2006, 35 (02) : 371 - +
  • [32] Molecular genetics of maturity-onset diabetes of the young
    Froguel, P
    Velho, G
    TRENDS IN ENDOCRINOLOGY AND METABOLISM, 1999, 10 (04): : 142 - 146
  • [33] Molecular genetics of maturity-onset diabetes of the young
    Voevoda, M. I.
    Ivanova, A. A.
    Shakhtshneider, E. V.
    Ovsyannikova, A. K.
    Mikhailova, S. V.
    Astrakova, K. S.
    Voevoda, S. M.
    Rymar, O. D.
    TERAPEVTICHESKII ARKHIV, 2016, 88 (04) : 117 - 124
  • [34] Novel gene mutation in maturity-onset diabetes of the young: A case report
    Zhang, Na
    Zhao, Hui
    Li, Cui
    Zhang, Feng-Zhi
    WORLD JOURNAL OF CLINICAL CASES, 2023, 11 (05) : 1099 - 1105
  • [35] Novel gene mutation in maturity-onset diabetes of the young: A case report
    Na Zhang
    Hui Zhao
    Cui Li
    Feng-Zhi Zhang
    World Journal of Clinical Cases, 2023, (05) : 1099 - 1105
  • [36] Maturity-onset diabetes of the young (MODY): current perspectives on diagnosis and treatment
    Urakami, Tatsuhiko
    DIABETES METABOLIC SYNDROME AND OBESITY-TARGETS AND THERAPY, 2019, 12 : 1047 - 1056
  • [37] Copy Number Variation in GCK in Patients With Maturity-Onset Diabetes of the Young
    Berberich, Amanda J.
    Huot, Celine
    Cao, Henian
    McIntyre, Adam D.
    Robinson, John F.
    Wang, Jian
    Hegele, Robert A.
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2019, 104 (08): : 3428 - 3436
  • [38] Liver and kidney function in Japanese patients with maturity-onset diabetes of the young
    Iwasaki, N
    Ogata, M
    Tomonaga, O
    Kuroki, H
    Kasahara, T
    Yano, N
    Iwamoto, Y
    DIABETES CARE, 1998, 21 (12) : 2144 - 2148
  • [39] MATURITY-ONSET DIABETES
    LLOYDMOSTYN, RH
    GOODFELLOW, RM
    BRITISH MEDICAL JOURNAL, 1979, 2 (6189): : 550 - 550
  • [40] MATURITY-ONSET DIABETES
    INGLIS, RJ
    BRITISH MEDICAL JOURNAL, 1979, 1 (6180): : 1795 - 1795